Whiterabbit
AI-driven solutions for early disease detection, enhancing compliance, revenue, and patient outcomes in breast health centers.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor | €0.0 | round |
* | N/A | - | |
| Total Funding | 000k | ||
![Follow[the]Seed](https://storage.googleapis.com/dealroom-images-production/78/NzQ6NzQ6Y29tcGFueUBzMy1ldS13ZXN0LTEuYW1hem9uYXdzLmNvbS9kZWFscm9vbS1pbWFnZXMvMjAxNy8wNS8yOS8zOGY4MmIyYWU0NWMwNDNkYTQzZTVlMzdmMmFhNGNlNg==.jpg){kind=small}
| USD | 2022 | 2023 |
|---|---|---|
| Revenues | 0000 | 0000 |
| EBITDA | 0000 | 0000 |
| Profit | 0000 | 0000 |
| EV | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 |
Source: Dealroom estimates
Related Content
Whiterabbit.ai operates in the healthcare technology sector, focusing on early detection of diseases through advanced artificial intelligence (AI) solutions. The company primarily serves breast health centers, radiologists, clinic operators, and payors. Its core product suite includes AI-powered tools designed to improve compliance, increase revenue, and enhance patient outcomes. Whiterabbit.ai leverages one of the world's largest radiology data sets to develop and validate its software, ensuring high accuracy and reliability. The business model revolves around selling its AI software solutions to healthcare providers, who benefit from improved diagnostic accuracy and operational efficiency. Revenue is generated through software licensing and service fees. The company aims to make late-stage diseases a rarity by enabling early detection and intervention.
Keywords: AI, healthcare technology, early detection, breast health, compliance, revenue, patient outcomes, radiology, software, diagnostics.